We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$20.4B
$119M 6.89%
700,000
-625,700
-47% -$117M
BIIB icon
2
CALL
Biogen
BIIB
$30.5B
$71.2M 4.13%
348,900
– –
SYK icon
3
PUT
Stryker
SYK
$129B
$58.7M 3.41%
295,000
+220,000
+293% +$51.7M
ILCV icon
4
PUT
iShares Morningstar Value ETF
ILCV
$1.35B
$58M 3.37%
1,150,000
-250,000
-18% -$16.2M
LIVN icon
5
CALL
LivaNova
LIVN
$4.29B
$54.3M 3.15%
869,100
+487,500
+128% +$34.5M
ESTA icon
6
Establishment Labs
ESTA
$2.69B
$53.8M 3.12%
988,713
+26,219
+3% +$1.66M
CUTR
7
DELISTED
Cutera, Inc.
CUTR
$41.9M 2.44%
1,118,158
+44,007
+4% +$2.32M
INSP icon
8
Inspire Medical Systems
INSP
$1.74B
$37.4M 2.17%
204,465
+1,023
+0.5% +$204K
XNTK icon
9
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.21B
$37.1M 2.16%
500,000
-891,800
-64% -$104M
VRAY
10
DELISTED
ViewRay, Inc.
VRAY
$36.8M 2.13%
13,869,108
+307,300
+2% +$925K
GKOS icon
11
Glaukos
GKOS
$10.1B
$36.2M 2.1%
+796,600
New +$37.8M
FXD icon
12
PUT
First Trust Consumer Discretionary AlphaDEX Fund
FXD
$276M
$34M 1.98%
330,000
+130,000
+65% +$6.5M
IDXX icon
13
PUT
Idexx Laboratories
IDXX
$46.1B
$29.8M 1.73%
+85,000
New +$34.7M
ARKG icon
14
PUT
ARK Genomic Revolution ETF
ARKG
$1.66B
$26.8M 1.55%
850,000
-1,400,000
-62% -$49M
MDT icon
15
PUT
Medtronic
MDT
$110B
$24.2M 1.41%
270,000
-90,000
-25% -$9.12M
GDX icon
16
PUT
VanEck Gold Miners ETF
GDX
$25.5B
$23.1M 1.34%
+300,000
New +$10.1M
ABT icon
17
PUT
Abbott
ABT
$183B
$21.7M 1.26%
200,000
+5,000
+3% +$568K
BIIB icon
18
Biogen
BIIB
$30.5B
$20.7M 1.2%
101,711
-45,424
-31% -$9.29M
MTD icon
19
PUT
Mettler-Toledo International
MTD
$28.5B
$20.1M 1.17%
17,500
+6,500
+59% +$8.17M
LUNG icon
20
Pulmonx
LUNG
$85M
$19.5M 1.13%
1,327,065
+737,343
+125% +$15.2M
GH icon
21
Guardant Health
GH
$21.9B
$18.9M 1.1%
469,492
+401,117
+587% +$19.9M
GH icon
22
CALL
Guardant Health
GH
$21.9B
$18.8M 1.09%
465,000
+190,000
+69% +$9.41M
NSTG
23
DELISTED
NanoString Technologies, Inc.
NSTG
$18.7M 1.08%
1,469,547
+249,215
+20% +$4.64M
ARKK icon
24
PUT
ARK Innovation ETF
ARKK
$6.05B
$17.9M 1.04%
450,000
-450,000
-50% -$21.4M
IMDX
25
Insight Molecular Diagnostics
IMDX
$161M
$16.2M 0.94%
902,814
+291,616
+48% +$6.63M
1
2 3 4 5

Similar funds

GMP
Great Mountain Partners New Haven, Connecticut $15.1M AUM 92.9% 1-Year Est. Return
BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.